Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Terns Pharmaceuticals Inc
TERNCurrent price
2.40 USD
+0.17 USD (+7.62%)
Last closed
2.00 USD
Company
www.ternspharma.com
ISIN
US8808811074
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
209 514 256 USD
Yield for 12 month
-50.21 %
1Y
3Y
5Y
10Y
15Y
TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Address: 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
19.06 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-881 000 USD
Current Quarter
–
Last Quarter
–
Key Figures TERN
1 year
3 years
5 years
10 years
EBITDA
-101 552 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-20.13 %
PEG Ratio
–
Return On Equity TTM
-29.56 %
Wall Street Target Price
19.06 USD
Revenue TTM
1 000 000 USD
Book Value
3.97 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
1 000 000 USD
Earnings per share
-1.12 USD
Diluted Eps TTM
-1.12 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics TERN
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History TERN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1000:50
Payout Ratio
–
Last Split Date
04.11.2013
Stock Valuation TERN
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
337.47
Price Sales TTM
302.64
Enterprise Value EBITDA
-5.80
Price Book MRQ
0.61
Financials TERN
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TERN
For 52 weeks
1.87 USD
11.40 USD
50 Day MA
3.29 USD
Shares Short Prior Month
5 947 873
200 Day MA
6.14 USD
Short Ratio
5.95
Shares Short
5 765 453
Short Percent
7.24 %
BeatStart